Ion Peptides
10 mg vial
- Vendor score
- 78/100
- Effective vial price
- Not available
- Effective price per mg
- Not available
ORView VendorPurchase link pending destination approval.
PDA (Pentadeca Arginate) is a compound commonly marketed around tissue or recovery research.
Also known as pda · pentadeca arginate · pentadeca-arginate
Research shortlist · Sep 12, 2026
These research selections use the same basis: 10 mg vial. The selections remain from Sep 12, 2026; each price below comes from its dated market observation.
10 mg vial
10 mg vial
10 mg vial
What it is
PDA (Pentadeca Arginate) is a compound commonly marketed around tissue or recovery research.
This label describes the available research record, not whether the compound is safe or effective for an individual.
Research context
5 registered studies were found under this name in the current review. Each study still needs to be checked for the exact compound identity, population, endpoints, and results.
Search indexed research for this compound ↗Market context
PDA (Pentadeca Arginate) is commonly sold or discussed for injury recovery, tissue repair, and inflammation research. That describes market demand, not proof that the compound is safe or effective.
Market demand and online discussion do not establish product quality, safety, or effectiveness.Same format. Same amount.
1 of 1 formats had a qualifying research shortlist on Sep 12, 2026. Vendor counts below reflect the available price observations.
Vendor directory
Grades describe the vendor record overall. They are not a test result for every product.
| Vendor | Grade | Compared offers | In stock when checked | Lowest effective package | Profile |
|---|---|---|---|---|---|
| EZ PeptidesVendor grade | Grade A- | 1 | 1 | $39.60Automatic buy x get y free · listed $4410 mg vial · compare →Observed Sep 21, 2026 | View → |
| Ameano PeptidesVendor grade | Grade B+ | 1 | 1 | $4410 mg vial · compare →Observed Sep 21, 2026 | View → |
| Ion PeptidesVendor grade | Grade B | Not available | Not available | Not availableNo market observation | View → |
Sources and review
Last editorial review: Aug 30, 2026. Sources support the compound guide only and do not affect vendor grades.